<DOC>
	<DOCNO>NCT02921724</DOCNO>
	<brief_summary>This prospective testing-validation , interventional , non-pharmacological study new app oral anticancer therapy management . A total 80 patient consider : 20 evaluable patient train step ; 60 patient validation step . In train step consider evaluable patient : least 6 week treatment ; visit 6 week start treatment perform questionnaires self-administered . Patients visit every 6 week . In train step , patient remain observation minimum 6 week , change therapy ( due progression disease , unacceptable toxicity , death , discontinuation ) maximum 12 week . Patients enrol validation step remain observation change therapy ( due progression disease , unacceptable toxicity , death , discontinuation ) maximum 24 week . The objective study ass capability newly develop interactive health care application support patient health professional share management oral anticancer therapy , improve adherence , prevent complication home , toxicity , improper treatment reduction interruption , emergency access assess system usability acceptability patient health professional , integration hospital workflow , monitoring time patient perceive level quality care , quality life , social support , anxiety , self-care capability .</brief_summary>
	<brief_title>Participatory Research Fine-tuning 2.0 System Optimise Home Management Oral Cancer Therapies .</brief_title>
	<detailed_description>This prospective , interventional , non pharmacological study testing-validation new app optimise home management oral therapy cancer treatment . All patient treat accord local clinical practice . Enrolment period : 8 ( train step ) + 12 ( validation step ) month . Total duration study : 36 month . This multicenter study . Objective study ass capability newly develop interactive health care application support patient health professional share management oral anticancer therapy , ass system usability acceptability patient health professional . Eligible patient must meet following criterion : - adult 18-75 year old ; - Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤ 1 ; - candidate treatment capecitabine sunitinib monotherapy ( adjuvant advance setting allow ) ; - sufficient ability manage mobile device basic train course hold baseline ; - clear understanding Italian language ; - write informed consent . Health professional patient define item system participatory design technique ( e.g . focus group session , joint review ) . To define whether system capable monitoring patient adherence , number pill count system ( self-reported patient home ) compare counted physician residual pill return patient hospital visit . A difference number pill within +/- 10 % consider acceptable . A comparison type grade toxicity make adverse event indicated system report patient clinical visit . The quality system consider adequate grade 3 least 80 % grade 2 toxicity data report patient time visit record app . To investigate system usability acceptability , Functional Assessment Cancer Therapy-General ( FACT-G ) Hospital Anxiety Depression Scale ( HADS ) questionnaires use . Scores subdivide different subscales analyze use Wilcoxon rank-sum test . Two new questionnaire develop used evaluate patient expectation system , system acceptability + patient-doctor communication . An internationally validated questionnaire translate Italian system usability ( SUS ) also administer end observation . Conversational interview audio-recorded , transcribed analyze .</detailed_description>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<criteria>ECOGPerformance Status ( PS ) less equal 1 ; life expectancy &gt; 12 week ; candidate treatment capecitabine sunitinib monotherapy ( adjuvant advance setting allow ) ; clear understanding Italian language ; subject , opinion Investigator , able understand study , cooperate study procedure able manage mobile device basic train course hold baseline ; write informed consent Patients receive also intravenous anticancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>oral drug</keyword>
	<keyword>sunitinib</keyword>
	<keyword>capecitabine</keyword>
	<keyword>mobile app</keyword>
</DOC>